BeiGene has become the first China A-share listed pharmaceutical company to reach a most-favored-nation (MFN) drug pricing agreement with the U.S. government. Announced by the White House on Aug. 31 U.S. local time, the voluntary agreement covers BeiGene's PD-1 inhibitor tislelizumab, sold as Tevimbra, which will be offered at negotiated prices to eligible patients through Medicaid (U.S. public health insurance jointly funded by federal and state governments). The company said the program reaches about 8% of Tevimbra's U.S.-approved indication patient base, while the agreement's price reduction, effective date and financial impact remain confidential. Its effect on BeiGene's results is expected to be limited because Zanubrutinib, marketed as Brukinsa, is the company's main U.S. revenue driver and is not covered. In the first half of 2026, BeiGene posted 22.22 billion yuan in operating revenue and 3.271 billion yuan in attributable net profit, up 26.8% and 627.1% year over year, respectively. Zanubrutinib generated 16.127 billion yuan in global sales, including 11.39 billion yuan in the U.S., while tislelizumab generated 2.984 billion yuan globally. Analysts and investment professionals described the agreement as a possible market-access experiment that trades lower prices for broader coverage and hospital access, while potentially reducing exposure to U.S. tariff or pricing-policy risks. The deal also highlights broader concerns that U.S. reference pricing could affect international pricing strategies and the valuation assumptions behind Chinese drugmakers' overseas licensing deals. BeiGene's future watch points include U.S. patient coverage for tislelizumab, whether volume offsets lower prices, and whether Zanubrutinib is eventually included in the MFN framework.